Table 2 Cytokine responses (geometric mean concentration (pg/mL) +1) and antibody levels (geometric mean concentration (μg/mL) +1) of cord blood by infection intensity and by treatment

IFNγ

placebo

2.28 (1.47, 3.53)

2.36 (1.19, 4.69)

2.57 (1.65, 3.99)

3.39 (1.65, 6.97)

praziquantel

3.18 (1.90, 5.34)

1.45 (1.01, 2.09)

1.84 (1.30, 2.60)

1.95 (1.08, 3.52)

IL-2

placebo

2.02 (1.40, 2.91)

3.07 (1.35, 6.96)

2.36 (1.57, 3.55)

4.65 (2.12, 10.2)

praziquantel

1.97 (1.31, 2.95)

2.44 (1.23, 4.83)

2.39 (1.47, 3.89)

1.67 (1.05, 2.64)

IL-4

placebo

1.39 (0.97, 1.98)

1.12 (0.89, 1.41)

1.29 (0.96, 1.73)

1.35 (0.87, 2.08)

praziquantel

1.79 (1.23, 2.60)

1.12 (0.94, 1.34)

1.53 (1.13, 2.08)

1.26 (0.90, 1.76)

IL-5

placebo

1.06 (0.97, 1.15)

1.73 (1.08, 2.77)

1.09 (1.00, 1.20)

1.57 (1.02, 2.40)

praziquantel

1.53 (1.09, 2.14)

1.36 (0.95, 1.96)

1.30 (1.02, 1.67)

1.46 (0.99, 2.16)

IL-13

placebo

1.22 (0.99, 1.51)

1.68 (1.04, 2.72)

1.76 (1.24, 2.50)

1.60 (1.06, 2.40)

praziquantel

1.49 (1.08, 2.05)

1.52 (0.84, 2.76)

1,40 (1.04, 1.87)

1.63 (0.92, 2.87)

IL-10

placebo

10.09 (5.38, 18.92)

6.72 (2.66, 17.04)

11.64 (5.95, 22.77)

10.32 (3.83, 27.8)

praziquantel

5.91 (3.18, 10.99)

7.40 (3.18, 17.23)

7.08 (3.69, 13.58)

5.96 (2.39, 14.87)

IgG1

placebo

39.87 (25.24, 62.99)

166.41 (104.02, 266.23)

53.94 (38.99, 74.63)

36.20 (21.16, 61.91)

praziquantel

73.70 (44.18, 122.94)

317.85 (243.33, 415.19)

46.22 (31.35, 68.15)

29.22 (17.16, 49.77)

IgG2

placebo

2.14 (1.72, 2.68)

4.48 (3.03, 6.62)

8.33 (6.70, 10.35)

7.12 (5.38, 9.43)

praziquantel

2.63 (2.04, 3.38)

5.80 (4.29, 7.84)

7.72 (5.99, 9.95)

6.49 (4.95, 8.52)

IgG3

placebo

1.79 (1.61, 2.00)

1.64 (1.45, 1.86)

1.28 (1.21, 1.36)

1.17 (1.10, 1.25)

praziquantel

1.59 (1.46, 1.73)

2.10 (1.77, 2.49)

1.24 (1.18, 1.31)

1.36 (1.23, 1.51)

IgG4

placebo

1.11 (0.96, 1.28)

2.24 (1.27, 3.97)

4.07 (3.24, 5.11)

7.32 (5.04, 10.6)

praziquantel

1.27 (1.01, 1.60)

2.96 (1.55, 5.65)

3.42 (2.71, 4.32)

7.61 (5.71, 10.16)